Literature DB >> 35300088

Novel Tricyclic Heteroaryl Compounds as IRAK4 Inhibitors for Treating Cancer, Autoimmune and Inflammatory Diseases.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2022        PMID： 35300088      PMCID： PMC8919273          DOI： 10.1021/acsmedchemlett.2c00060

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  6 in total

Review 1.  Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors.

Authors:  Jiamin Zheng; Jun Wu; Xiao Ding; Hong C Shen; Ge Zou
Journal:  Bioorg Med Chem Lett       Date:  2021-02-18       Impact factor: 2.823

Review 2.  14-3-3 modulation of the inflammatory response.

Authors:  Claire C Munier; Christian Ottmann; Matthew W D Perry
Journal:  Pharmacol Res       Date:  2020-10-11       Impact factor: 7.658

Review 3.  IRAK family in inflammatory autoimmune diseases.

Authors:  Lin-Chong Su; Wang-Dong Xu; An-Fang Huang
Journal:  Autoimmun Rev       Date:  2020-01-07       Impact factor: 9.754

Review 4.  Chemical reagents modulate nucleic acid-activated toll-like receptors.

Authors:  Xiao Li; Xinyuan Sun; Xuemin Guo; Xueren Li; Shouchun Peng; Xin Mu
Journal:  Biomed Pharmacother       Date:  2022-01-07       Impact factor: 6.529

Review 5.  Creating Awareness for Primary Immunodeficiencies in Japan.

Authors:  Hidetoshi Takada
Journal:  Front Immunol       Date:  2021-12-13       Impact factor: 7.561

Review 6.  IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies.

Authors:  Joshua Bennett; Daniel T Starczynowski
Journal:  Curr Opin Hematol       Date:  2022-01-01       Impact factor: 3.284
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.